Citi Comments on Apellis Pharmaceuticals (APLS), Moves PT to $106

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. SWKS
7. ANET
8. SPY
9. XYZ
10. CVS

Go back to Citi Comments on Apellis Pharmaceuticals (APLS), Moves PT to $106

Apellis Pharmaceuticals Reports First Quarter 2023 Financial Results

May 4, 2023 4:05 PM EDT

Generated U.S. net product revenues of $18.4 million for SYFOVRE (pegcetacoplan injection) and $20.4 million for EMPAVELI® (pegcetacoplan) SYFOVRE launched in the U.S. as the first and only treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD)Validation received for marketing applications for intravitreal pegcetacoplan in the EU, Canada, Australia, the United Kingdom, and Switzerland; decisions expected in the first half of 2024 Cash and cash equivalents of $765 million as of March 31, 2023; expected cash... More

Apellis Pharmaceuticals to Present at the Bank of America Securities 2023 Healthcare Conference

May 3, 2023 7:00 AM EDT

WALTHAM, Mass., May 03, 2023 (GLOBE NEWSWIRE) --... More